Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + BDB001 + Radiotherapy in Advanced Solid Tumors
NCT03915678Phase 2Active, not recruiting
- Sponsor
- Institut Bergonié
- Start
- Mar 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of BDB001 in pancreatic cancer (PC), tumor, non-small cell lung cancer (NSCLC) and 3 more (6 arms), sponsored by Institut Bergonié. Primary endpoint: Assessment of the antitumor activity at 6 months. Started Mar 2021; status: active, not recruiting.
02
Drugs
BDB001
03
Conditions
pancreatic cancer (PC)tumornon-small cell lung cancer (NSCLC)soft tissue sarcoma (STS)bladder cancer
Beyond the preview
Go deeper on NCT03915678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915678.